|

Clemastine Fumarate Clinical Trials

2 actively recruiting trials across 2 locations

▼ -1 trial since May 2026

Also known as: Clemastine, Dayhist, Dayhist Allergy, Tavegyl, clemastine

Pipeline

Phase 1/2: 2

Top Sponsors

  • University of California, San Francisco1
  • National Institute of Allergy and Infectious Diseases (NIAID)1

Indications

  • Multiple Sclerosis2
  • Multiple Sclerosis Benign1
  • Multiple Sclerosis Brain Lesion1
  • Multiple Sclerosis Relapse1
  • Multiple Sclerosis, Chronic Progressive1

San Francisco, California1 trial

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Sandler Neurosciences Building, Neurological Clinical Research Unit

Phase 1/2

Bethesda, Maryland1 trial

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

National Institutes of Health Clinical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.